Changes

==Gene Overview==

==Gene Overview==

The ABL1 gene encodes for a  non-receptor tyrosine kinase that is ubiquitously expressed and involved in a large number of cellular processes (see '''[https://www.ncbi.nlm.nih.gov/gene/25#reference-sequences "NCBI Gene]''').  While very few substitution mutations in ABL1 have been found in A reciprocal translocation between chromosome 22 (BCR locus)  and chromosome 9 (ABL1 locus) produces the Philadelphia chromosome t(9;22)(q34.1;q11.2), which is prevalent in Chronic Myeloid Leukemia (1, 2) and to a lesser extent in B-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Leukemia. The head to tail arrangement of the BCR-ABL1 fusion gene results in an activated tyrosine kinase activity.  A number of other gene fusion partners have been identified with ABL1 and linked to other hematological cancers, but at a much smaller prevalence than BCR-ABL1.  They include NUP214 (associated with T-cell Acute Lymphoblastic Leukemia), ETV6 (associated with Chronic Myeloid Leukemia, T-cell Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia  and Acute Myeloid Leukemia), and EML (associated with T-cell Acute Lymphoblastic Leukemia)

The ABL1 gene encodes for a  non-receptor tyrosine kinase that is ubiquitously expressed and involved in a large number of cellular processes (see '''[https://www.ncbi.nlm.nih.gov/gene/25#reference-sequences "NCBI Gene]''').  While very few substitution mutations in ABL1 have been found in A reciprocal translocation between chromosome 22 (BCR locus)  and chromosome 9 (ABL1 locus) produces the Philadelphia chromosome t(9;22)(q34.1;q11.2), which is prevalent in Chronic Myeloid Leukemia (1, 2) and to a lesser extent in B-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Leukemia. The head to tail arrangement of the BCR-ABL1 fusion gene results in an activated tyrosine kinase activity.  A number of other gene fusion partners have been identified with ABL1 and linked to other hematological cancers, but at a much smaller prevalence than BCR-ABL1.  They include NUP214 (associated with T-cell Acute Lymphoblastic Leukemia), ETV6 (associated with Chronic Myeloid Leukemia, T-cell Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia  and Acute Myeloid Leukemia), and EML (associated with T-cell Acute Lymphoblastic Leukemia).

The ABL1 and ABL2 genes encode tyrosine kinases which share overlapping physiological roles andABL2 fusions are found in other hematological cancers, including

 

The ABL1 and ABL2 genes encode tyrosine kinases which share overlapping physiological roles and ABL2 somatic or amplification mutations are more common than similar mutations in ABL1.  Somatic mutations for ABL1 have been found in Lung Squamous Cell Carcinomas patients (2%), Uterine Corpus Endometrioid Carcinoma  patients (3%) and in less than 1% of patients with Breast Invasive Carcinoma, Ovarian Serous Cystadenocarcinoma, and Lung Adenocarcinoma (6)

==Common Alteration Types==

==Common Alteration Types==